Hematology

Older African American multiple myeloma patients have lower rates of access to autologous stem cell transplants and and novel combination therapies.

Elderly African American multiple myeloma patients had lower rates of access to autologous stem cell transplant.

Selinexor combined with liposomal doxorubicin and dexamethasone shows promise.

Patients administered high levels of methotrexate showed impaired cognitive function and altered brain anatomy.

Bortezomib and dexamethasone slowed disease progression in patients with recurrent or refractory multiple myeloma.

Ninety-three percent of B-cell acute lymphoblastic leukemia patients treated went into remission in small study.

Patients with multiple myeloma receiving ASCT showed a 10% increase in tumor cell reduction.

Genetic variation can cause severe acute pancreatitis from chemotherapy in patients with acute lymphoblastic leukemia (ALL).

Treatment of elderly patients with multiple myeloma creates unique hurdles for care providers.

Ibrutinib evaluated in the treatment of chronic lymphocytic leukemia, Waldenström macroglobulinaemia, and mantle cell lymphoma.

Imbruvica approved for use in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Imbruvica approved for use in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Levels of TJP1 could potentially determine an effective treatment for patients with multiple myeloma.

Biomarker can help determine the most effective treatment for patients with multiple myeloma.

Patients taking mitoxantrone for multiple sclerosis found to have higher rates of breast and colorectal cancers and leukemia.

Patients administered mitoxantrone for multiple sclerosis carry higher rates of breast and colorectal cancers and leukemia.

Blincyto granted priority status to treat a form of acute lymphoblastic leukemia.

Animal model of malignant plasma-cell disease may accelerate new treatments for multiple myeloma.

Rapamycin may effectively treat patients with venous malformations.

The cost of oral cancer drugs spiked six-fold within the last 14 years.

Methotrexate and decadron could lower relapse rates of patients with acute lymphoblastic leukemia.

Medi-551 antibody targets the protein CD19 found on the surface of multiple myeloma stem cells.

Anti-CD38 monoclonal antibody daratumumab (Darzalex) shows promise for patients with multiple myeloma.

All-oral treatment regimen improves response rate in multiple myeloma.

Single-cell method identifies core stem cells that cause leukemia within a tumor.